There is no established medication to treat expressive aphasia caused by long-term antipsychotic use
The primary intervention for expressive aphasia from any cause, including antipsychotic-induced cases, is speech-language therapy—not medication. The evidence provided addresses aphasia from stroke and other neurological causes, but does not support pharmacological treatment for antipsychotic-induced expressive aphasia specifically.
Critical First Step: Discontinue or Reduce the Offending Antipsychotic
Before considering any treatment for the aphasia itself, you must address the underlying cause:
Evaluate whether the antipsychotic can be discontinued or dose-reduced 1. The WHO guidelines recommend that withdrawal may be considered in individuals stable for several years on antipsychotic treatment, keeping in mind increased relapse risk 1.
If the patient requires continued antipsychotic treatment, consider switching to an atypical antipsychotic with a lower risk of neurological side effects 2. Atypical agents have diminished risk of extrapyramidal symptoms compared to typical antipsychotics 2.
Monitor for improvement after dose reduction or medication change, as drug-induced neurological effects may be partially reversible.
Speech-Language Therapy is the Evidence-Based Treatment
The most recent high-quality evidence strongly supports speech-language therapy as the primary intervention:
Provide higher total SLT dose (≥20 hours) with higher intensity and frequency to improve outcomes 3. This 2025 European Stroke Organisation guideline, while focused on stroke-related aphasia, represents the best available evidence for aphasia rehabilitation generally.
Individually-tailored SLT should be the foundation of treatment 3.
Computer-based therapy is feasible and efficacious and can supplement treatment provided by a speech-language pathologist 4.
Pharmacological Augmentation: Limited and Uncertain Evidence
If you consider medication to augment speech therapy (not as monotherapy), the evidence is weak and primarily from stroke-related aphasia:
Cholinergic agents show the most promise:
- Donepezil has preliminary evidence from case series and open-label studies suggesting benefit in chronic aphasia 5. It appears well-tolerated with maintained long-term efficacy, though randomized controlled trials are still needed 5.
Dopaminergic agents have mixed evidence:
- Bromocriptine may be useful in nonfluent aphasias with reduced initiation of spontaneous verbal messages 5, 6, but evidence is controversial 6.
- The mechanism may involve enhancing activation and initiation of verbal output 6.
Important caveats:
- Piracetam showed weak evidence of benefit in stroke-related aphasia 7, but concerns about increased death rates (though not statistically significant) limit its use 7.
- Most pharmacological studies focused on stroke-related aphasia, not drug-induced aphasia 8, 5, 9.
- Improvement tends to be most prominent in patients with mild-to-moderate severity rather than severe aphasia 6.
Avoid Common Pitfalls
Do not use anticholinergic medications (like benztropine or trihexyphenidyl) to treat extrapyramidal symptoms from antipsychotics 2, as these will worsen cognitive and language function.
Do not continue typical antipsychotics if alternatives exist—they carry a 50% risk of tardive dyskinesia after 2 years of continuous use in elderly patients 2.
Do not expect medication alone to resolve aphasia—speech-language therapy must be the cornerstone 4, 3, 10.
Recognize that antipsychotic-induced aphasia may represent a broader neurotoxic effect requiring comprehensive neurological evaluation, not just symptomatic treatment of the language deficit.